The Company recently announced formal approval of blueprints for the construction and expects to break ground before the end of October. Once the construction is complete and the facility becomes fully operational, it is projected to generate $450 million in annual revenue, including $300 million from standard IV bags and $150 million from premixed drug IV bags.

The facility is planned within the Marion 9 Biomanufacturing Center at the Atlas Complex and demonstrates Callan JMB’s previously announced pharmaceutical manufacturing initiative with Alabama State University. The blueprint approval significantly advanced the project and provided the design basis to break ground to construct a state-of-the-art facility combining automated production with quality-control and advanced distribution capabilities.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.